Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

Condition:   Colorectal Cancer Metastatic Interventions:   Drug: Tunlametinib plus Vemurafenib;   Drug: Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab Sponsor:   Shanghai Kechow Pharma, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials